{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T16:32:54Z","timestamp":1793032374471,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,11,20]],"date-time":"2023-11-20T00:00:00Z","timestamp":1700438400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["cell.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["iScience"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.isci.2023.108541","type":"journal-article","created":{"date-parts":[[2023,11,22]],"date-time":"2023-11-22T22:04:02Z","timestamp":1700690642000},"page":"108541","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":27,"title":["3BP-3940, a highly potent FAP-targeting peptide for theranostics - production, validation and first in human experience with Ga-68 and Lu-177"],"prefix":"10.1016","volume":"26","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4040-8468","authenticated-orcid":false,"given":"Lukas","family":"Greifenstein","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Gunkel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aileen","family":"Hoehne","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Osterkamp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christiane","family":"Smerling","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christian","family":"Landvogt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corinna","family":"Mueller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard P.","family":"Baum","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.isci.2023.108541_bib1","doi-asserted-by":"crossref","first-page":"4396","DOI":"10.1007\/s00259-021-05475-0","article-title":"State-of-the-art of FAPI-PET imaging: a systematic review and meta-analysis","volume":"48","author":"Sollini","year":"2021","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.isci.2023.108541_bib2","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13225744","article-title":"Radioligands Targeting Fibroblast Activation Protein (FAP)","volume":"13","author":"Lindner","year":"2021","journal-title":"Cancers"},{"key":"10.1016\/j.isci.2023.108541_bib3","doi-asserted-by":"crossref","DOI":"10.3390\/biomedicines10030523","article-title":"Imaging Cancer-Associated Fibroblasts (CAFs) with FAPi PET","volume":"10","author":"Gilardi","year":"2022","journal-title":"Biomedicines"},{"key":"10.1016\/j.isci.2023.108541_bib4","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/s41573-018-0004-1","article-title":"Turning foes to friends: targeting cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2019","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.isci.2023.108541_bib5","doi-asserted-by":"crossref","first-page":"454","DOI":"10.1002\/prca.201300095","article-title":"Understanding fibroblast activation protein (FAP): substrates, activities, expression and targeting for cancer therapy","volume":"8","author":"Hamson","year":"2014","journal-title":"Proteomics. Clin. Appl."},{"key":"10.1016\/j.isci.2023.108541_bib6","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1021\/acsmedchemlett.9b00191","article-title":"Novel Small Molecule-Derived, Highly Selective Substrates for Fibroblast Activation Protein (FAP)","volume":"10","author":"De Decker","year":"2019","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.isci.2023.108541_bib7","doi-asserted-by":"crossref","first-page":"3412","DOI":"10.1016\/j.bmcl.2012.03.107","article-title":"Acylated Gly-(2-cyano)pyrrolidines as inhibitors of fibroblast activation protein (FAP) and the issue of FAP\/prolyl oligopeptidase (PREP)-selectivity","volume":"22","author":"Ryabtsova","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"10.1016\/j.isci.2023.108541_bib8","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.118.215913","article-title":"(68)Ga-FAPI PET\/CT: Biodistribution and Preliminary Dosimetry Estimate of 2 DOTA-Containing FAP-Targeting Agents in Patients with Various Cancers","volume":"60","author":"Giesel","year":"2019","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.isci.2023.108541_bib9","doi-asserted-by":"crossref","first-page":"1421","DOI":"10.2967\/jnumed.118.224469","article-title":"Development of Fibroblast Activation Protein-Targeted Radiotracers with Improved Tumor Retention","volume":"60","author":"Loktev","year":"2019","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.isci.2023.108541_bib10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.2967\/jnumed.119.227967","article-title":"(68)Ga-FAPI PET\/CT: Tracer Uptake in 28 Different Kinds of Cancer","volume":"60","author":"Kratochwil","year":"2019","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.isci.2023.108541_bib11","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1186\/s41181-020-00102-z","article-title":"Targeting fibroblast activation protein (FAP): next generation PET radiotracers using squaramide coupled bifunctional DOTA and DATA(5m) chelators","volume":"5","author":"Moon","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.isci.2023.108541_bib12","first-page":"727","article-title":"Initial Clinical Experience with (90)Y-FAPI-46 Radioligand Therapy for Advanced-Stage Solid Tumors: A Case Series of 9 Patients","volume":"63","author":"Ferdinandus","year":"2022","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.isci.2023.108541_bib13","doi-asserted-by":"crossref","first-page":"4346","DOI":"10.1158\/1078-0432.CCR-22-1432","article-title":"Safety and Efficacy of 90Y-FAPI-46 Radioligand Therapy in Patients with Advanced Sarcoma and Other Cancer Entities","volume":"28","author":"Fendler","year":"2022","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.isci.2023.108541_bib14","doi-asserted-by":"crossref","first-page":"1000","DOI":"10.3390\/ph15081000","article-title":"From Automated Synthesis to In\u00a0Vivo Application in Multiple Types of Cancer\u2014Clinical Results with [68Ga]Ga-DATA5m.SA.FAPi","volume":"15","author":"Greifenstein","year":"2022","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.isci.2023.108541_bib15","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1055\/a-1164-5667","article-title":"[68Ga]Ga-DATA5m.SA.FAPi PET\/CT: Specific Tracer-uptake in Focal Nodular Hyperplasia and potential Role in Liver Tumor Imaging","volume":"59","author":"Kreppel","year":"2020","journal-title":"Nuklearmedizin"},{"key":"10.1016\/j.isci.2023.108541_bib16","doi-asserted-by":"crossref","DOI":"10.3390\/ph14121212","article-title":"First-In-Human Results on the Biodistribution, Pharmacokinetics, and Dosimetry of [(177)Lu]Lu-DOTA.SA.FAPi and [(177)Lu]Lu-DOTAGA.(SA.FAPi)(2)","volume":"14","author":"Ballal","year":"2021","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.isci.2023.108541_bib17","first-page":"476","article-title":"Fibroblast Activation Protein (FAP) targeting homodimeric FAP inhibitor radiotheranostics: a step to improve tumor uptake and retention time","volume":"11","author":"Moon","year":"2021","journal-title":"Am. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.isci.2023.108541_bib18","doi-asserted-by":"crossref","first-page":"3651","DOI":"10.1007\/s00259-022-05842-5","article-title":"Preclinical evaluation of FAP-2286 for fibroblast activation protein targeted radionuclide imaging and therapy","volume":"49","author":"Zboralski","year":"2022","journal-title":"Eur. J. Nucl. Med. Mol. Imaging"},{"key":"10.1016\/j.isci.2023.108541_bib19","doi-asserted-by":"crossref","first-page":"415","DOI":"10.2967\/jnumed.120.259192","article-title":"Feasibility, Biodistribution, and Preliminary Dosimetry in Peptide-Targeted Radionuclide Therapy of Diverse Adenocarcinomas Using (177)Lu-FAP-2286: First-in-Humans Results","volume":"63","author":"Baum","year":"2022","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.isci.2023.108541_bib20","doi-asserted-by":"crossref","first-page":"386","DOI":"10.2967\/jnumed.122.264544","article-title":"PET imaging of fibroblast activation protein in various types of cancers by using (68)Ga-FAP-2286: Comparison with (18)F-FDG and (68)Ga-FAPI-46 in a single-center, prospective study","volume":"64","author":"Pang","year":"2023","journal-title":"J.\u00a0Nucl. Med."},{"key":"10.1016\/j.isci.2023.108541_bib21","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1186\/s41181-019-0086-z","article-title":"EANM guideline on the validation of analytical methods for radiopharmaceuticals","volume":"5","author":"Gillings","year":"2020","journal-title":"EJNMMI Radiopharm. Chem."},{"key":"10.1016\/j.isci.2023.108541_bib22","doi-asserted-by":"crossref","DOI":"10.1155\/2017\/8160134","article-title":"Labelling of 177Lu-DOTA-Bioconjugates for Targeted Radionuclide Therapy: A Comparison Among Manual, Semiautomated, and Fully Automated Synthesis","volume":"2017","author":"Iori","year":"2017","journal-title":"Contrast Media Mol. Imaging"},{"key":"10.1016\/j.isci.2023.108541_bib23","first-page":"72","article-title":"Automated module radiolabeling of peptides and antibodies with gallium-68, lutetium-177 and iodine-131","volume":"27","author":"De Decker","year":"2012","journal-title":"Cancer Biother. Radiopharm."}],"container-title":["iScience"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223026184?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589004223026184?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,8]],"date-time":"2025-11-08T19:34:35Z","timestamp":1762630475000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589004223026184"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S2589004223026184"],"URL":"https:\/\/doi.org\/10.1016\/j.isci.2023.108541","relation":{},"ISSN":["2589-0042"],"issn-type":[{"value":"2589-0042","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"3BP-3940, a highly potent FAP-targeting peptide for theranostics - production, validation and first in human experience with Ga-68 and Lu-177","name":"articletitle","label":"Article Title"},{"value":"iScience","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.isci.2023.108541","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Author(s).","name":"copyright","label":"Copyright"}],"article-number":"108541"}}